Rob Hopfner, RPh, PhD, MBA, is a Managing Director of Bay City Capital and has been with the firm since 2002. Dr. Hopfner brings a unique combination of drug discovery, product development, and commercial and business development expertise to his investments. He has a strong track record of working successfully with entrepreneurs to get novel, important medicines through development and onto the market.
He led or co-led investments in Aciex Therapeutics (sold to Nicox S.A.), Cydan, Civitas Therapeutics (sold to Acorda Therapeutics), Dermira (NASDAQ: DERM), Hyperion Therapeutics (sold to Horizon Pharma), Imara Therapeutics, Merus B.V. (NASDAQ: MRUS), NextWave Pharmaceuticals (sold to Pfizer), Pharmakea Therapeutics, Tetraphase Pharmaceuticals (NASDAQ: TTPH), and Vtesse (sold to Sucampo Pharmaceuticals). He is currently a board member or board observer on Cydan, Imara Pharmaceuticals, and Pharmakea Therapeutics.
Before joining Bay City Capital, Dr. Hopfner worked in DuPont Pharmaceuticals’ Business Development & Strategic Planning group and at Ag-West Biotech, a Western Canadian seed-stage biotech venture capital firm. Dr. Hopfner holds a PhD in Pharmacology and a degree in Pharmacy from the University of Saskatchewan, and an MBA from the University of Chicago Booth School of Business. His biomedical research focused on endocrine pharmacology and he completed his post-doctoral work at Harvard Medical School. Dr. Hopfner won numerous awards during his research career, including the Governor General of Canada Gold Medal Award in 2000, and he published several articles in top medical journals based on his work.